Hydroxychloroquine: How Did We Get Here?  [Talk #1 with Dr. Udupa]

1) Briefly discuss the history, structure, pharmacokinetics, proposed MOAs, and autoimmune disease benefits of HCQ.

2) Briefly describe the winding road that eventually led to the repurposing of HCQ for the treatment of SARS-CoV-2 infection.

3) Map out short term and long term research goals.

Evaluating health care disparities in cardiovascular outcomes and secondary prevention strategies in African American patients with rheumatoid arthritis  [Talk #2 with Dr. Smith]

1) Review cardiovascular outcomes in patients with rheumatoid arthritis 

2) Explore health care disparities in African American patients with rheumatoid arthritis

3) Outline second-year research project on cardiovascular disease in African American patients with rheumatoid arthritis  

Disclosures: 

None

CME Code: PANNEF

Location: virtual (by WebEx only)

Directions: see attachment (PDF) in prior email on How to Download WebEx

Streaming: Yes, via WebEx.  Link:  Click to Join

[Meeting Number (Access Code): 738 886 371 > you will not need this if you use link above]